2026-526307-30-00招募中4 期
A study to compare how 2 different formulations of survodutide are taken up in the body when given by injection in healthy men and women with and without overweight or obesity
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 44
- 试验地点
- 3
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
CT Disclosure & Data Transparency
Scientific
Boehringer Ingelheim International GmbH
研究点 (3)
Loading locations...
相似试验
已完成
1 期
A research study comparing the effect of different dosing conditions on blood levels of semaglutide in a new tablet composition in healthy participantsType 2 Diabetes2023-503949-65-00Novo Nordisk A/S120
招募中
1 期
A study to test whether different combinations of BI 765063, ezabenlimab, chemotherapy, cetuximab, and BI 836880 help people with head and neck cancer or liver cancerhepatocellular carcinoma2024-512799-36-00Boehringer Ingelheim International GmbH18
招募中
1 期
An exploratory study to investigate the effect of FE 999302 when given together with follitropin delta during controlled ovarian stimulation2023-507630-25-00Ferring Pharmaceuticals A/S600
尚未招募
不适用
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared with Placebo in Adults with Type 2 Diabetes Mellitus on
Background Insulin (Eluminate-3)Type 2 Diabetes MellitusjRCT203126026280
招募中
不适用
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared With Elecoglipron Alone and Dapagliflozin Alone, in Adults With Type 2 Diabetes Mellitus (Eluminate-5)Type 2 Diabetes MellitusjRCT2031260261165